Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Tryptamine Therapeutics ( (AU:ENP) ) is now available.
Entropy Neurodynamics Limited has applied for quotation on the ASX of 1,200,000 new ordinary fully paid shares under code ENP. The securities, issued on March 10, 2026, arise from the exercise or conversion of existing options or other convertible instruments, modestly expanding the company’s listed share capital and potentially enhancing its liquidity and funding flexibility.
The additional quoted securities may marginally dilute existing shareholders but can support the company’s capital structure as it advances its neurotechnology-related activities. The move signals ongoing utilisation of equity-based instruments within the company’s financing strategy and maintains regulatory compliance with ASX listing requirements.
The most recent analyst rating on (AU:ENP) stock is a Sell with a A$0.03 price target. To see the full list of analyst forecasts on Tryptamine Therapeutics stock, see the AU:ENP Stock Forecast page.
More about Tryptamine Therapeutics
Entropy Neurodynamics Limited is an ASX-listed company trading under the ticker ENP. The firm operates in the broader neurotechnology and life sciences space, with its activities focused on developing and commercialising neuroscience-related technologies or therapeutics, although the specific products and market segments are not detailed in this filing.
Average Trading Volume: 2,424,495
Technical Sentiment Signal: Sell
Current Market Cap: A$53.31M
See more data about ENP stock on TipRanks’ Stock Analysis page.